{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T02:58:38Z","timestamp":1784689118322,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.seizure.2016.01.017","type":"journal-article","created":{"date-parts":[[2016,2,13]],"date-time":"2016-02-13T16:11:21Z","timestamp":1455379881000},"page":"16-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["The efficacy, tolerability and safety of levetiracetam therapy in a pediatric population"],"prefix":"10.1016","volume":"36","author":[{"given":"Hasan","family":"Tekg\u00fcl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Gencpinar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"\u00c7avu\u015fo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihal Olga\u00e7","family":"D\u00fcndar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2016.01.017_bib0150","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0920-1211(01)00296-0","article-title":"A systematic review of the safety profile of levetiracetam: a new antiepileptic drug","volume":"47","author":"French","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2016.01.017_bib0155","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Commission on Classification and Terminology of the International League Against Epilepsy: proposal for revised classification of epilepsies and epileptic syndromes","volume":"30","year":"1989","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2016.01.017_bib0160","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40263-015-0248-9","article-title":"Levetiracetam monotherapy in children with epilepsy: a systematic review","volume":"29","author":"Weijenberg","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2016.01.017_bib0165","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1177\/08830738040190120601","article-title":"Retrospective study of the use of levetiracetam in childhood seizure disorders","volume":"19","author":"Koukkari","year":"2004","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2016.01.017_bib0170","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pediatrneurol.2006.09.018","article-title":"Levetiracetam monotherapy in children with epilepsy","volume":"36","author":"Khurana","year":"2007","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2016.01.017_bib0175","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/0883073807309784","article-title":"Levetiracetam versus carbamazepine monotherapy for partial epilepsy in children less than 16 years of age","volume":"23","author":"Perry","year":"2008","journal-title":"J Child Neurol"},{"key":"10.1016\/j.seizure.2016.01.017_bib0180","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00431-013-2125-1","article-title":"Initial anticonvulsant monotherapy in routine care of children and adolescents: levetiracetam fails more frequently than valproate and oxcarbazepine due to a lack of effectiveness","volume":"173","author":"Bertsche","year":"2014","journal-title":"Eur J Pediatr"},{"key":"10.1016\/j.seizure.2016.01.017_bib0185","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/jpc.12494","article-title":"The efficacy and safety of levetiracetam in paediatric patients treated with chemotherapeutic agents for haematologic disorders","volume":"50","author":"Bayram","year":"2014","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.seizure.2016.01.017_bib0190","first-page":"100","article-title":"New onset paediatric epilepsy in 1-5 years age group children \u2013 approach to management in a tertiary care centre with newer anti-epileptic levetiracetam","volume":"112","author":"Barik","year":"2014","journal-title":"J Indian Med Assoc"},{"key":"10.1016\/j.seizure.2016.01.017_bib0195","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.seizure.2004.10.004","article-title":"Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial","volume":"14","author":"Lagae","year":"2005","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2016.01.017_bib0200","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1684\/j.1950-6945.2005.tb00127.x","article-title":"Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes","volume":"7","author":"Di Bonaventura","year":"2005","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2016.01.017_bib0205","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.seizure.2006.12.006","article-title":"Levetiracetam monotherapy for children and adolescents with benign rolandic seizures","volume":"16","author":"Verrotti","year":"2007","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2016.01.017_bib0210","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.pediatrneurol.2007.06.019","article-title":"Levetiracetam monotherapy in newly diagnosed cryptogenic West syndrome","volume":"37","author":"G\u00fcm\u00fcs","year":"2007","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2016.01.017_bib0215","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.yebeh.2007.07.011","article-title":"A pilot study transitioning children onto levetiracetam monotherapy to improve language dysfunction associated with benign rolandic epilepsy","volume":"11","author":"Kossoff","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2016.01.017_bib0220","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1469-8749.2007.02009.x","article-title":"Levetiracetam in juvenile myoclonic epilepsy: long-term efficacy in newly diagnosed adolescents","volume":"50","author":"Verrotti","year":"2008","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.seizure.2016.01.017_bib0225","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/j.1469-8749.2008.03099.x","article-title":"Levetiracetam in absence epilepsy","volume":"50","author":"Verrotti","year":"2008","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.seizure.2016.01.017_bib0230","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1600-0404.2009.01264.x","article-title":"Levetiracetam monotherapy for childhood occipital epilepsy of gastaut","volume":"120","author":"Verrotti","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2016.01.017_bib0235","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.seizure.2010.01.003","article-title":"Levetiracetam in the treatment of neonatal seizures: a pilot study","volume":"19","author":"F\u00fcrwentsches","year":"2010","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2016.01.017_bib0240","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.braindev.2010.03.002","article-title":"Efficacy and tolerability of levetiracetam in children with epilepsy","volume":"33","author":"Li","year":"2011","journal-title":"Brain Dev"},{"key":"10.1016\/j.seizure.2016.01.017_bib0245","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.braindev.2006.09.008","article-title":"Levetiracetam or oxcarbazepine as monotherapy in newly diagnosed benign epilepsy of childhood with centrotemporal spikes (BECTS): an open-label, parallel group trial","volume":"29","author":"Coppola","year":"2007","journal-title":"Brain Dev"},{"key":"10.1016\/j.seizure.2016.01.017_bib0250","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1136\/jnnp-2011-301999","article-title":"The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy\u2014an open-label, prospective, randomised controlled multicenter study","volume":"83","author":"Rosenow","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.seizure.2016.01.017_bib0255","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejpn.2013.07.003","article-title":"Continuation rates of levetiracetam in children from the EULEVp cohort study","volume":"18","author":"Dureau-Pournin","year":"2014","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.seizure.2016.01.017_bib0260","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.yebeh.2006.11.016","article-title":"Levetiracetam in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center","volume":"10","author":"Bootsma","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2016.01.017_bib0265","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejpn.2014.11.001","article-title":"Retention rates of levetiraceram in Chinese children and adolescents with epilepsy","volume":"19","author":"Feng","year":"2015","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.seizure.2016.01.017_bib0270","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.seizure.2014.06.004","article-title":"Behavioral side-effects of levetiracetam in children with epilepsy: a systematic review","volume":"23","author":"Halma","year":"2014","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2016.01.017_bib0275","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.pediatrneurol.2015.01.012","article-title":"Correlation between efficacy of levetiracetam and serum levels among children with refractory epilepsy","volume":"52","author":"Sheinberg","year":"2015","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2016.01.017_bib0280","unstructured":"http:\/\/www.fda-reports.com\/keppra\/reaction\/enuresis\/page1.html [accessed 02.09.15]."},{"key":"10.1016\/j.seizure.2016.01.017_bib0285","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.seizure.2012.10.003","article-title":"Effects of levetiracetam on seizure frequency and neuropsychological impairments in children with refractory epilepsy with secondary bilateral synchrony","volume":"22","author":"Kanemura","year":"2013","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2016.01.017_bib0290","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1111\/j.1528-1167.2005.00337.x","article-title":"Levetiracetam efficacy in epileptic syndromes with continuous spikes and waves during slow sleep: experience in 12 cases","volume":"46","author":"Aeby","year":"2005","journal-title":"Epilepsia"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105913111600039X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S105913111600039X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:46:50Z","timestamp":1761011210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S105913111600039X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":29,"alternative-id":["S105913111600039X"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2016.01.017","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy, tolerability and safety of levetiracetam therapy in a pediatric population","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2016.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}